Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyMedical Mutual - Ohio Cholbam Prior Auth Coverage …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Cholbam (cholic acid) recommended authorization criteria

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for recommended prior authorization and coverage criteria for Cholbam (cholic acid) under the pharmacy benefit, including indications, required documentation, prescriber specialty, and approval durations. Applies to providers seeking coverage for members under medical mutual - ohio.

    Policy Summary
    Payermedical mutual - ohio
    PolicyCholbam (cholic acid) recommended authorization criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateMay 21, 2026
    Last ReviewMay 21, 2026
    Next Review DateMay 21, 2026
    Key ActionObtain prior authorization and ensure Cholbam is prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90Initial approval duration
    365Extended approval duration
    4Recommended criteria groups
    RequiredSpecialist prescriber

    Coverage Criteria for Cholbam (cholic acid)

    Bile Acid Synthesis Disorders Due to Single Enzyme Defects (SEDs), Initial Therapy

    Covered when ALL of the following are met

    SEDs initial criteria: A. Diagnosis of bile acid synthesis disorder due to single enzyme defects (SEDs); AND B. Diagnosis based on an abnormal urinary bile acid confirmed by Fast Atom Bombardment ionization - Mass Spectrometry (FAB‑MS) OR molecular genetic testing consistent with the diagnosis; AND C. Documentation of liver function testing within the past 6 months (e.g., AST, ALT, GGT, ALP, bilirubin, INR); AND D. Cholbam is prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.

    Bile Acid Synthesis Disorders Due to Single Enzyme Defects (SEDs), Continuing Therapy

    Covered when ALL of the following are met

    SEDs continuation criteria: A. Patient has responded to initial Cholbam therapy with improvement in liver function tests (e.g., AST, ALT, GGT, ALP, bilirubin, INR); AND B. Patient does not have complete biliary obstruction; AND C. Cholbam is prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.

    Peroxisomal Disorders (PDs), Including Zellweger Spectrum Disorders, Initial Therapy

    Covered when ALL of the following are met

    PD initial criteria: A. Diagnosis of peroxisomal disorder, including Zellweger Spectrum Disorder; AND B. Diagnosis based on abnormal urinary bile acid analysis by Fast Atom Bombardment ionization - Mass Spectrometry (FAB‑MS) OR molecular genetic testing consistent with the diagnosis; AND C. Presence of liver disease, steatorrhea, or complications from decreased fat‑soluble vitamin absorption (e.g., rickets); AND D. Documentation of liver function testing within the past 6 months (e.g., AST, ALT, GGT, ALP, bilirubin, INR); AND E. Cholbam is prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.

    Peroxisomal Disorders (PDs), Including Zellweger Spectrum Disorders, Continuing Therapy

    Covered when ALL of the following are met

    PD continuation criteria: A. Patient has responded to initial Cholbam therapy as per the prescribing physician (e.g., improvements in liver enzymes, improvement in steatorrhea); AND B. Patient does not have complete biliary obstruction; AND C. Cholbam is prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.

    Combination therapy of Cholbam (cholic acid) with chenodeoxycholic acid products such as Chenodal or Ctexli is not recommended because there are no efficacy data to support combined use. In addition, coverage is not recommended for circumstances that are not specifically listed in the Recommended Authorization Criteria; the criteria will be updated if new published data become available.

    Uses of Cholbam that are not listed in the Recommended Authorization Criteria should not be approved routinely. Such requests require case‑by‑case review with supporting clinical evidence and documentation; the Company may deny reimbursement when the service is determined to be not medically necessary, investigational, experimental, or outside the member’s benefits. Providers should be prepared to submit relevant records, test results, and provider credentials when requested to support medical necessity.

    Testing and Laboratory Documentation Requirements

    Liver function testing — required panels and recency
    Required testsAST, ALT, GGT, ALP, bilirubin, and INR
    Recency requirementDocumentation of the above liver function tests within the past 6 months
    PurposeDemonstrates baseline or ongoing hepatic function to support initiation or continuation of Cholbam
    Referenced in criteriaRequired for both SEDs (initial therapy) and PDs (initial therapy) coverage criteria

    Actions Required from Prescribers and Documentation to Support Prior Authorization

    Prior Authorization

    Prior authorization and specialist prescriber requirement

    Prior authorization is recommended for pharmacy benefit coverage of Cholbam. Initial approval requires the drug be prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.

    • All approvals for initial therapy are provided for the initial approval duration; reauthorization requires demonstration of response to therapy unless otherwise noted.
    Step Therapy

    Do not combine Cholbam with Chenodal or Ctexli

    Combination therapy with chenodeoxycholic acid (Chenodal) or Ctexli is not recommended because there are no efficacy data available to support use of combination therapy with Cholbam.

    • Coverage for combination use is listed under Conditions Not Recommended for Approval.
    Documentation Required

    Required documentation and test recency

    Include diagnostic confirmation and recent liver testing in the request: abnormal urinary bile acid confirmed by FAB‑MS or molecular genetic testing, and liver function tests within the past 6 months (AST, ALT, GGT, ALP, bilirubin, INR). The Company may request additional records to support medical necessity.

    • Diagnostic confirmation: abnormal urinary bile acid by Fast Atom Bombardment‑Mass Spectrometry (FAB‑MS) OR molecular genetic testing consistent with diagnosis.
    • Liver function testing documented within the past 6 months: AST, ALT, GGT, ALP, bilirubin, and INR.
    • Be prepared to provide patient records, test results, and provider credentials if requested.
    Denial Risk

    Denial risk: insufficient medical necessity or documentation

    The Company may deny reimbursement when the drug or services are not medically necessary, investigational or experimental, not within the scope of member benefits, or when documentation is inappropriate, excessive, or unavailable upon request.

    • Failure to provide additional requested documentation (e.g., patient records, test results, provider credentials) may result in denial.
    • Requests for uses not listed in the Recommended Authorization Criteria may be denied as investigational or not medically necessary.

    Background and Indications

    Cholbam (cholic acid) is indicated for treatment of bile acid synthesis disorders due to single enzyme defects (SEDs) and may be used as adjunctive therapy for peroxisomal disorders (PDs), including Zellweger spectrum disorders, when patients have liver disease, steatorrhea, or complications from decreased fat‑soluble vitamin absorption. Diagnosis for SEDs and PDs should be confirmed by abnormal urinary bile acid analysis (FAB‑MS) or molecular genetic testing. Prior authorization requests should include recent liver function testing within the past 6 months (AST, ALT, GGT, ALP, bilirubin, INR), and Cholbam should be prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist. The drug’s effects on extrahepatic manifestations (for example, neurologic features) of SEDs are not established.

    Definitions of Disorders

    SEDs — diagnostic criteria and acceptable tests
    Diagnostic confirmation methodsAbnormal urinary bile acid analysis confirmed by Fast Atom Bombardment ionization‑Mass Spectrometry (FAB‑MS) OR molecular genetic testing consistent with diagnosis
    Clinical diagnosisDiagnosis of bile acid synthesis disorder due to single enzyme defects (SEDs)
    Prescriber requirementCholbam must be prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist
    Related monitoringDocumentation of liver function testing within past 6 months (AST, ALT, GGT, ALP, bilirubin, INR) is required
    Peroxisomal disorders — diagnostic criteria and acceptable tests
    Diagnostic confirmation methodsAbnormal urinary bile acid analysis by Fast Atom Bombardment ionization‑Mass Spectrometry (FAB‑MS) OR molecular genetic testing consistent with diagnosis
    Clinical diagnosisDiagnosis of peroxisomal disorder, including Zellweger Spectrum Disorder
    Clinical indication for treatmentPresence of liver disease, steatorrhea, or complications from decreased fat‑soluble vitamin absorption (e.g., rickets)
    Prescriber requirementCholbam must be prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist
    Related monitoringDocumentation of liver function testing within past 6 months (AST, ALT, GGT, ALP, bilirubin, INR) is required
    Policy Summary
    Payermedical mutual - ohio
    PolicyCholbam (cholic acid) recommended authorization criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateMay 21, 2026
    Last ReviewMay 21, 2026
    Next Review DateMay 21, 2026
    Key ActionObtain prior authorization and ensure Cholbam is prescribed by or in consultation with a hepatologist, metabolic specialist, or gastroenterologist.
    SourceLink
    On This Page
    Coverage Criteria for Cholbam (cholic acid)Testing and Laboratory Documentation RequirementsActions Required from Prescribers and Documentation to Support Prior AuthorizationBackground and IndicationsDefinitions of Disorders

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.